Skip to main content
NCBI home page
Medicine logoLink to Medicine
. 2019 Nov 15;98(46):e17896. doi: 10.1097/MD.0000000000017896

The expression of ubiquitin-conjugating enzyme E2C and KAI1 in ovarian carcinoma and their clinical significance

Yingying Gong a, Danna Wang b,c, Lu Lin a, Junjun Dai a, Lan Yu b,c,∗
Editor: Uddyalok Banerjee
PMCID: PMC6867754  PMID: 31725636

Abstract

Ubiquitin-conjugating enzyme E2C (UBE2C) is considered to play an important role in the tumorigenesis of many cancers and promote cell cycle progression. Kangai 1 (KAI1) is considered as a suppressor gene of tumor metastasis. However, the clinicopathological significance and their each relationship of UBE2C and KAI1 in epithelial ovarian carcinoma (EOC) are not widely reported. The purpose of this study is to detect the expression of UBE2C and KAI1 in EOC and their clinical significance.

The expression of UBE2C and KAI1 in 180 cases of EOC tissues, 60 cases of normal ovarian epithelial tissues, and 60 cases of ovarian benign tumor tissues were detected by immunohistochemistry. Patients data were also collected.

Positive expression of UBE2C in EOC (38.9%) was significantly higher than that both in the normal group (0%) and benign tumors group (10.0%). Furthermore, the expression of UBE2C was positively associated with grades of differentiation, implants, lymph node metastasis (LNM), as well as the International Federation of Gynecology and Obstetrics (FIGO) stages. Positive expression of KAI1 in EOC (25.0%) was significantly lower than that both in the normal group (100%) and benign tumors group (75.0%). And the expression of KAI1 was inversely associated with grades of differentiation, implants, LNM, and FIGO stages. Kaplan–Meier survival analyses demonstrated that UBE2C positive expression for patients with EOC had unfavorably overall survival (OS) time when compared with negative UBE2C for patients. And KAI1 positive expression for patients had favorably OS time when compared with negative KAI1 for patients. Multivariate analysis showed that positive expression of UBE2C and KAI1, implants, and FIGO stages were considered as independently prognostic factors for OS in patients with EOC. Moreover, UBE2C expression was significantly higher in high grade serous adenocarcinoma (SA) when compared with low grade SA; and KAI1 expression was significantly lower in high grade SA when compared with low grade SA. High grade SA patients had higher rates of implants, LNM, and high FIGO stages when compared with low grade SA. High grade SA patients had unfavorably OS time when compared with low grade SA.

UBE2C and KAI1 should be considered as potential biomarkers of EOC prognosis.

Keywords: EOC, immunohistochemistry, KAI1, prognosis, UBE2C

1. Introduction

An estimated 239 thousand new ovarian cancer cases and 152 thousand deaths worldwide occurred in 2012.[1] And there were an estimated 52 thousand new ovarian cancer cases and 22 thousand deaths China in 2015.[2] Epithelial ovarian carcinoma (EOC) which accounts for 85% approximately is the most common type.[3] Because of insidious onset, more than 70% of EOC patients were at advanced stage when diagnosed. EOC is a group of highly heterogeneous cancers which makes it urgent to find some biomarkers for early evaluation of progression and prognosis. Ubiquitin-conjugating enzyme E2C (UBE2C), a key part of the ubiquitin-conjugating enzyme complex, is an important member of the E2 family. UBE2C gene, which is located on human chromosome 20q13, encodes 19.6 kDa protein and is involved in the destruction of mitotic system. UBE2C can promote cell cycle progression and strengthen genetic stability.[4] UBE2C expression is extremely low in normal tissue. Aberrant expression of UBE2C may suppress the autoregulatory feedback loop for the regulation of antigen-presenting cells and cause the dysregulation of cell growth.[5,6] Accumulating evidence showed that overexpression of UBE2C may be involved in various biological processes, including tumorigenesis, proliferation, cycle, and apoptosis.[6–10]

Tumor invasiveness and metastasis are closely associated with the inactivation of tumor metastasis suppressor gene. KAI1, also named as CD82, is originally found in prostate cancer cell lines.[11]KAI1 gene, which is located on human chromosome 11p11.2, is widely reported as a suppressor gene of tumor metastasis.[11]KAI1 gene that contains 10 exons and 9 introns is an important member of the transmembrane 4 protein superfamily.[12] KAI1 plays an important role not only in extensive physiological processes, but also in pathological processes such as tumor invasion and metastasis.[13,14] KAI1 can strengthen cell to cell adhesion and cell to extracellular matrix (ECM) by enhancing the stabilization of E-cadherin/β-catenin complex to inhibit metastasis.[15] Increasing evidence has indicated that down- or lost-expression of KAI1 should be involved in cancer cell proliferation, progression, fusion, motility, migration, invasion, and metastasis.[16]

Overall, the studies of UBE2C and KAI1 have demonstrated that they should be associated with cancer invasion and metastasis. However, the clinicopathological significance of UBE2C and KAI1 in EOC are not widely reported. The purpose of this study is to analyze the association between UBE2C and KAI1 as well as with metastasis and prognosis of EOC's patients.

2. Methods

2.1. Patients and samples

All samples were collected from 180 patients who were diagnosed EOC at the Department of Pathology of the First Affiliated Hospital of Bengbu Medical University. The median age of patients was 55.8 years and time was from January 2010 to December 2012. Sixty cases of normal ovarian epithelial tissues and 60 cases of benign ovarian tumors (such as serous or mucinous cystadenoma) were also collected in the same period. Patients who had underwent any history anticancer therapy were excluded. The data of patients consisted of clinicopathological characteristics, demography, and follow-up time. Follow-up time was calculated from removal date to December 2017 or her death date (median age was 49.1 months, range 6–93 months). Grades of differentiation were assessed in accordance with the guidelines issued by the World Health Organization. Tumor-node-metastasis stages were assessed in accordance with the guideline issued by the 2015th version of the International Federation of Gynecology and Obstetrics (FIGO). The type of implants as follows: serous type had 56 cases of implant; mucinous type had 9 cases of implants; endometrial type had 7 cases of implant; clear cell type had 3 cases of implants. Tissue samples were obtained with each patients’ consents and the research was approved by the ethical committee of Bengbu Medical University and conducted in accordance with the guidelines issued of the Declaration of Helsinki. Specific clinicopathological characteristics see Table 1.

Table 1.

Patients characteristics.

2.1.

Open in a new tab

2.2. Immunohistochemistry

All EOC and control samples were fixed in 10% buffered formalin, then embedded in paraffin. 4 μm thickening sections were cut. Deparaffinized and dehydrated were used in the xylene solution and gradient alcohol solution. Immunohistochemistry was performed according to ElivisionTM Plus method (Lab Vision, Fremont, CA) and the procedure was carried out in accordance with the kit instructions. Rabbit anti-human monoclonal antibody against UBE2C and mouse anti-human monoclonal antibody against KAI1 were both purchased from Abcam, Co, Ltd. (San Francisco, CA) Other reagents (such as diaminobenzidine [DAB], reagent A, and reagent B) were purchased from Fuzhou Maixin Biotechnology Development Co, Ltd (China). Antigen repair was in the citrate buffer solution (pH 6.0) and endogenous peroxidase activity of all samples was quenched by 3% H2O2 solution. All sections were incubated by goat serum for 30 minutes. Then, UBE2C and KAI1 primary antibodies were added and incubated overnight at 4°C. Subsequently, reagent A (polymer enhancer) and reagent B (goat anti-mouse antibody) were added. Finally, all sections were developed in DAB substrate solution and re-dyed with hematoxylin.

2.3. Assessment of immunohistochemical staining

Ten high-power-field fields of each EOC section was chosen to prevent possible intratumoral heterogeneity of biomarker expression. Final immunostaining results were reached by multiplying the score of staining intensity (0 means no staining; 1 means weak staining; 2 means moderate staining; 3 means strong staining.) and the score of staining extent (1 means <11% positive cells; 2 means 11%–50% positive cells; 3 means 51%–75% positive cells; 4 means >75% positive cells). The final immunostaining scores were from 0 to 12. The determination of the immunostaining results was considered as positive (score >2). The average score of all sections was taken.

2.4. Statistical analysis

Chi-square test was used to evaluate the positive expression of UBE2C and KAI1 in EOC and the control samples, as well as the associations between both 2 biomarkers expression and clinicopathological characteristics of EOC. Overall survival (OS) analysis was conducted used log-rank test with the Kaplan–Meier method. Multivariate OS analysis was conducted using Cox regression model test. Correlation coefficient analysis was performed using the Spearman correlation test. P < .05 was defined as statistically significant differences.

3. Results

3.1. Associations between UBE2C and KAI1 expression in EOC and clinicopathological characteristics

The positive expression of UBE2C was mainly located in both the nuclei and cytoplasm. The positive expression of UBE2C in EOC samples (38.9%, 70/180) was significantly higher than that in the control samples (10.0%, 6/60) (Fig. 1A and B). Furthermore, the positive expression of UBE2C in EOC was significantly associated with grades of differentiation, implants, lymph node metastasis (LNM), as well as FIGO stages. Furthermore, UBE2C expression was significantly higher in high grade serous adenocarcinoma (SA) when compared with low grade SA. And there was no association between positive expression of UBE2C and EOC patients age, tumor size, location, histological type, and ascites (Table 2).

Figure 1.

Figure 1

Open in a new tab

Immunostaining of UBE2C or KAI1 in EOC or the control tissues (400 magnification). (A) Negative staining of UBE2C in the control tissues; (B) positive staining of UBE2C in nuclei and cytoplasm of the EOC cells; (C) positive staining of KAI1 in the membrane and cytoplasm of the EOC cells; (D) negative staining of KAI1 in the EOC cells. EOC = epithelial ovarian carcinoma, UBE2C = ubiquitin-conjugating enzyme E2C.

Table 2.

Correlation between the expression of UBE2C and KAI1 and clinicopathological characteristics in EOC.

3.1.

Open in a new tab

The positive expression of KAI1 was mainly located in both the membrane and cytoplasm. The positive expression of KAI1 in EOC samples (25.0%, 45/180) was significantly lower than that in the control samples (75.0%, 45/60) (Fig. 1C and D). In addition, the positive expression of KAI1 in EOC was inversely associated with grades of differentiation, implants, LNM, and FIGO stages. And there was no association between KAI1 expression and patients age, tumor size, location, histological type, as well as ascites (Table 2). Moreover, KAI1 expression was significantly lower in high grade SA when compared with low grade SA. High grade SA patients had higher rates of implants, LNM and high FIGO stages when compared with low grade SA patients (all P < .05).

3.2. Association between UBE2C expression and KAI1 expression in EOC

There was a negative association between UBE2C expression and KAI1 expression (r = −0.329, P < .05) (Table 3).

Table 3.

The association between UBE2C and KAI1 expression and clinicopathological characteristics in EOC.

3.2.

Open in a new tab

3.3. Univariate and multivariate analyze

As shown in Figure 2A, OS analysis indicated that the OS of patients with UBE2C-positive ovarian tumors was significantly lower than that of patients with UBE2C-negative tumors (log-rank = 22.185, P < .001). As shown in Figure 2B, OS analysis indicated that the OS of patients with KAI1-positive ovarian tumors was significantly higher than that of patients with KAI1-negative tumors (log-rank = 20.960, P < .001). In univariate analysis, OS time was significantly associated with the following clinicopathological characteristics, grades of differentiation (log-rank = 8.426, P = .004; Fig. 2C), implants (log-rank = 47.021, P < .001; Fig. 2D), LNM (log-rank = 14.971, P < .001; Fig. 2E), as well as FIGO stages (log-rank = 39.558, P < .001; Fig. 2F) (Table 4). High grade SA tumors had unfavorably OS time when compared with low grade SA tumors (log-rank = 12.012, P = .001; Fig. 2G). Patients with UBE2C-negative/KAI1-positive expression had favorable OS time when compared with UBE2C-positive/KAI1-negative expression group or UBE2C-negative/KAI1-negative expression group (log-rank = 36.214, P < .001; Fig. 2H). In metastasis-free patients, KAI1-positive expression had a favorable OS time when compared with KAI1-negative expression (log-rank = 16.135, P < .001; Fig. 2I).

Figure 2.

Figure 2

Open in a new tab

Kaplan–Meier analysis of the survival rate of patients with EOC. The y-axis represents the percentage of patients; the x-axis represents their survival in months. (A) OS of all patients in relation to UBE2C (log-rank= 22.185, P < .001); (B) OS of all patients in relation to KAI1 expression (log-rank = 20.960, P < .001); In A-B analyses, the green line represents patients with positive expression of biomarkers and the blue line representing the negative expression of biomarkers. (C) OS of all patients in relation to grades of differentiation (log-rank = 8.426, P = .004; the blue line represents patients with low grades, the green line represents patients with high grades); (D) OS of all patients in relation to implants (log-rank = 47.021, P < .001; the blue line represents patients with no implants group, the green line represents patients with implants group); (E) OS of all patients in relation to LNM (log-rank = 14.971, P < .001; the blue line represents patients with no LNM group, the green line represents patients with yes LNM group); (F) OS of all patients in relation to FIGO stages (log-rank = 39.558, P < .001; the blue line represents patients with I + II stages; the green line represents patients with III + IV stages). (G) OS of all patients in relation to differentiation of serous adenocarcinoma (log-rank = 12.012, P = .001; the blue line represents patients with low-grade serous adenocarcinoma; the green line represents patients with high-grade serous adenocarcinoma). (H) OS of all patients in relation to coexpression of UBE2C and KAI1 (log-rank = 36.214, P < .001; the blue line represents patients with UBE2C+ KAI1−; the green line represents patients with UBE2C− KAI1+; the brown line represents patients with UBE2C+ KAI1+; the purple line represents patients with UBE2C− KAI1−). (I) OS of metastasis-free patients in relation to KAI1 expression (log-rank = 16.135, P < .001; the blue line represents patients with KAI1-negative expression; the green line represents patients with KAI1-positive expression). EOC = epithelial ovarian carcinoma, FIGO = International Federation of Gynecology and Obstetrics, LNM = lymph node metastasis, OS = overall survival, UBE2C = ubiquitin-conjugating enzyme E2C.

Table 4.

Results of univariate analyses of overall survival (OS) time.

3.3.

Open in a new tab

Multivariate analysis of OS demonstrated that positive expression of UBE2C and KAI1, implants, and FIGO stages were independently prognostic factors affecting patients’ OS time (Table 5).

Table 5.

Results of multivariate analyses of overall survival (OS) time.

3.3.

Open in a new tab

4. Discussion

Ovarian cancer is the fifth most common malignant tumor in women. Due to the heterogeneity of EOC, it seriously threatens the health and lives of women. It is an urgent need to study pathogenesis of EOC and comprehensively and thoroughly assesses effectiveness of EOC biomarkers. UBE2C is an important regulator of degradation of mitotic cyclins, regulation of anaphase-promoting complex, as well as cell cycle progression.[17,18] Overexpression of UBE2C can promote tumor cell proliferation and malignant transformation.[6] In this study, positive expression of UBE2C was significantly higher in EOC samples than that in the control samples. Furthermore, overexpression of UBE2C was significantly associated with grades of differentiation, implants, LNM, as well as FIGO stages. OS survival demonstrated that positive expression of UBE2E for EOC's patients had an unfavorable OS time when compared with negative for UBE2C. These findings demonstrated that overexpression of UBE2C should promote EOC invasion and metastasis, should be considered a useful biomarker for prediction of prognosis which is consistent with the previous studies.[19–22]

Inactivation of tumor metastasis suppressor genes is an important step in tumor invasion and metastasis. KAI1, which belongs to the transmembrane 4 superfamily, is widely considered as a suppressor of tumor metastasis. KAI1 suppresses tumor metastasis through not only inhibiting cell motility, but also suppressing degradation of the ECM.[23] In this study, positive expression of KAI1 in EOC's samples was significantly lower than that in the control samples. Moreover, positive expression of KAI1 was inversely associated with grades of differentiation, implants, LNM, and FIGO stages. Kaplan–Meier OS analysis demonstrated that EOC's patients with KAI1+ had a favorable OS time when compared with KAI1− for patients. The above results indicated that down- or lost-expression of KAI1 should promote tumor cell invasion and metastasis and mean an unfavorable prognosis. Therefore, KAI1 should be considered a useful and valuable biomarker for prediction of metastasis and prognosis of EOC which are similar to the previous studies.[13,14,16,24,25]

In this study, multivariate analysis demonstrated that positive expression of UBE2C and KAI1, implants, and FIGO stages were independent prognostic factors of OS for EOC's patients. Moreover, UBE2C expression was significantly higher in high grade SA when compared with low grade SA; and KAI1 expression was significantly lower in high grade SA when compared with low grade SA. High grade SA patients had higher rates of implants, LNM, and high FIGO stages when compared with low grade SA. High grade SA patients had unfavorably OS time when compared with low grade SA. Spearman coefficient analysis demonstrated that UBE2C expression was negatively associated with KAI1 expression. It is well known that FIGO stages’ system is a crucial guide for determining the clinical therapeutic strategies of EOC. However, FIGO stage's system does not fully show the biological behavior of EOC. So, it is urgent need to find some biomarkers for prediction of tumor invasion, metastasis, and prognosis for EOC. UBE2C is involved in the ubiquitin-proteasome proteolytic pathway which is able to initiate aberrant degradation of proteins encoded by oncogenes and suppressor genes. This may cause aberrant accumulation of these proteins in some organs.[19] UBE2C may promote cells proliferation, viability, motility, and migration in vitro.[26,27] Knockdown of UBE2C can lower tumorigenesis.[28] Downregulation of UBE2C is able to inhibit N-cadherin expression and enhance E-cadherin expression.[29,30] Overexpression of UBE2C can promote tumor cell proliferation and malignant transformation and maybe lost promotion of E-cadherin expression which will lead to invade and metastatic. In the same time, down- or lost-expression of KAI1 should lost enhancing stability of E-cadherin/β-catenin complex, this should further promote tumor cell invasion and metastasis. However, the number of specimens in this study is relatively small. Further studies with larger sized specimens, including in vitro, in vivo, and molecular experiment, are needed to support the present observations.

5. Conclusions

Our study indicated that UBE2C and KAI1 are associated with OS time of patients with EOC. Therefore, UBE2C and KAI1 should be considered to show the progression and prognosis of EOC, as well as provide a promising choice of therapeutic target.

Acknowledgment

We thank all staff at the Department of Pathology of our hospital for assistance with data and project management.

Author contributions

Conceptualization: Lan Yu.

Data curation: Yingying Gong.

Funding acquisition: Lan Yu.

Investigation: Lu Lin, Junjun Dai.

Methodology: Danna Wang.

Resources: Lu Lin.

Software: Lu Lin, Junjun Dai.

Validation: Lan Yu.

Writing – original draft: Yingying Gong.

Writing – review and editing: Yingying Gong.

Footnotes

Abbreviations: DAB = diaminobenzidine, ECM = extracellular matrix, EOC = epithelial ovarian carcinoma, FIGO = International Federation of Gynecology and Obstetrics, LNM = lymph node metastasis, OS = overall survival, SA = serous adenocarcinoma, UBE2C = ubiquitin-conjugating enzyme E2C.

How to cite this article: Gong Y, Wang D, Lin L, Dai J, Yu L. The expression of ubiquitin-conjugating enzyme E2C and KAI1 in ovarian carcinoma and their clinical significance. Medicine. 2019;98:46(e17896).

YG and DW contributed equally to this work.

This work was supported by the Nature Science Key Program of College and the University of Anhui Province (No. KJ2017A224).

All tissue specimens were obtained with patients writing extensively informed consent when they were in hospital and the study was approved by the Bengbu Medical University ethical committee and performed in accordance with the ethical guidelines of the Declaration of Helsinki before it started.

The authors have no conflicts of interest to disclose.

References

  • [1].Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108. [DOI] [PubMed] [Google Scholar]
  • [2].Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32. [DOI] [PubMed] [Google Scholar]
  • [3].Kim J, Coffey DM, Creighton CJ, et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A 2012;109:3921–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [4].van Ree JH, Jeganathan KB, Malureanu L, et al. Overexpression of the E2 ubiquitin–conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol 2010;188:83–100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].Troncone G, Guerriero E, Pallante P, et al. UbcH10 expression in human lymphomas. Histopathology 2009;54:731–40. [DOI] [PubMed] [Google Scholar]
  • [6].Okamoto Y, Ozaki T, Miyazaki K, et al. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res 2003;63:4167–73. [PubMed] [Google Scholar]
  • [7].Li SZ, Song Y, Zhang HH, et al. UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer. Sci Rep 2014;4:6910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8].Endesfelder D, Burrell R, Kanu N, et al. Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer. Cancer Res 2014;74:4853–63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Chang L, Zhang Z, Yang J, et al. Atomic structure of the APC/C and its mechanism of protein ubiquitination. Nature 2015;522:450–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Zhang Z, Liu P, Wang J, et al. Ubiquitin-conjugating enzyme E2C regulates apoptosis-dependent tumor progression of non-small cell lung cancer via ERK pathway. Med Oncol 2015;32:149. [DOI] [PubMed] [Google Scholar]
  • [11].Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11P11.2. Science 1995;268:884–6. [DOI] [PubMed] [Google Scholar]
  • [12].Marx J. New clue to prostate cancer spread. Science 1995;268:799–800. [DOI] [PubMed] [Google Scholar]
  • [13].Yang YG, Sari IN, Zia MF, et al. Tetraspanins: spanning from solid tumors to hematologic malignancies. Exp Hematol 2016;44:322–8. [DOI] [PubMed] [Google Scholar]
  • [14].Richardson MM, Jennings LK, Zhang XA. Tetraspanins and tumor progression. Clin Exp Metastasis 2011;28:261–70. [DOI] [PubMed] [Google Scholar]
  • [15].Abe M, Sugiura T, Takahashi M, et al. A novel function of CD82/KAI-1 on E-cadherin-mediated homophilic cellular adhesion of cancer cells. Cancer Lett 2008;66:163–70. [DOI] [PubMed] [Google Scholar]
  • [16].Miranti CK. Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis. Cell Signal 2009;21:196–211. [DOI] [PubMed] [Google Scholar]
  • [17].Summers MK, Pan B, Mukhyala K, et al. The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC. Mol Cell 2008;31:544–56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [18].Williamson A, Wickliffe KE, Mellone BG, et al. Identification of a physiological E2 module for the human anaphase-promoting complex. Proc Natl Acad Sci U S A 2009;106:18213–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19].Mo CH, Gao L, Zhu XF, et al. The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data. Cancer Cell Int 2017;17:83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20].Wang W, Wang Z, Zhao J, et al. A novel molecular and clinical staging model to predict survival for patients with esophageal squamous cell carcinoma. Oncotarget 2016;7:63526–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Peng ZM, Yu W, Xie Y, et al. A four actin-binding protein signature model for poor prognosis of patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol 2014;7:5950–9. [PMC free article] [PubMed] [Google Scholar]
  • [22].Kim WT, Jeong P, Yan C, et al. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria. Oncotarget 2016;7:58193–202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23].Aram R, Dotan I, Hotz-Wagenblatt A, et al. Identification of a novel metastasis inducing lncRNA which suppresses the KAI1/CD82 metastasis suppressor gene and is upregulated in triple-negative breast cancer. Oncotarget 2017;8:67538–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Ci H, Xu Z, Xu J, et al. Expressions of KAI1 and E-cadherin in nonsmall cell lung cancer and their correlation with vasculogenic mimicry. Medicine (Baltimore) 2018;97:e12293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25].Zheng Z, Tian R, Wang P. Roles of KAI1 and nm23 in lymphangiogenesis and lymph metastasis of laryngeal squamous cell carcinoma. World J Surg Oncol 2017;15:211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26].Shuliang S, Lei C, Guangwu J, et al. Involvement of ubiquitin-conjugating enzyme E2C in proliferation and invasion of prostate carcinoma cells. Oncol Res 2013;21:121–7. [DOI] [PubMed] [Google Scholar]
  • [27].Tang XK, Wang KJ, Tang YK, et al. Effects of ubiquitin-conjugating enzyme 2C on invasion, proliferation and cell cycling of lung cancer cells. Asian Pac J Cancer Prev 2014;15:3005–9. [DOI] [PubMed] [Google Scholar]
  • [28].Wang R, Song Y, Liu X, et al. UBE2C induces EMT through Wnt/β-catenin and PI3K/Akt signaling pathways by regulating phosphorylation levels of Aurora-A. Int J Oncol 2017;50:1116–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29].Radice GL. N-cadherin-mediated adhesion and signaling from development to disease: lessons from mice. Prog Mol Biol Transl Sci 2013;116:263–89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Lee JY, Kong G. Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression. Cell Mol Life Sci 2016;73:4643–60. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health

RESOURCES